Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment

    loading  Checking for direct PDF access through Ovid


We investigated the effects of hepatic and renal impairment on the pharmacokinetics of enrofloxacin in Sprague-Dawley rats. Experimental hepatic and renal failure were induced by carbon tetrachloride (CCL4) and 5/6 nephrectomy, respectively. After intravenous dosing of enrofloxacin (10 mg/kg), plasma concentrations of enrofloxacin were measured using liquid chromatograph/mass spectrometry. There was no significant effect of hepatic impairment on enrofloxacin pharmacokinetics. However, renal impairment markedly prolonged elimination half life (t1/2λz) of enrofloxacin (P<0.05), comparing with respective control. Total body clearance (Clb) and volume of distribution at steady state (Vss) were significantly decreased (P<0.05) by renal impairment. In conclusion, these results suggested that renal impairment could affect the pharmacokinetics of enrofloxacin.

Related Topics

    loading  Loading Related Articles